RxDoctor Payments Data

Adam Burroughs, MD

Interventional Cardiology · Oklahoma City, OKNPI 1134488281

Payments from drug & device makers

$2,085in general payments, 2019–2025

Across 120 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$729
  • Pfizer$186
  • GE HealthCare$174
  • Inari Medical, Inc.$164
  • Surmodics, Inc.$132
  • Actelion Pharmaceuticals US, Inc.$102
  • plus $599 from 14 others

What the payments were for

  • Food & beverage$2,085100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,085 in reported general payments places this provider in the 20th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$279,105
Medicare patients
1,952
Services billed
4,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban393$395,165
EntrestoSacubitril/Valsartan86$83,527
XareltoRivaroxaban11$14,743
Metoprolol Succinate362$4,724
Atorvastatin Calcium404$4,693
Midodrine Hcl18$2,153
Pravastatin Sodium60$2,118
Rosuvastatin Calcium143$2,093
Ranolazine ErRanolazine14$2,020
Amlodipine Besylate201$1,885
Carvedilol207$1,699
Losartan Potassium115$1,555
Torsemide78$1,485
Metoprolol Tartrate127$1,060
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$1,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$395,165393 claims
NovartisEntresto$57$83,52786 claims
Johnson & JohnsonXarelto$48$14,74311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →